Specific gene mutations in L5178Y cells in culture

Mutation Research
|June 1, 1983
PubMed

Insights

The L5178Y mouse lymphoma cell assay effectively screens for mutagenicity, identifying 39 of 48 agents. While generally versatile, it showed some false positives and negatives when compared to carcinogenicity data.

Area of Science:

  • Biochemistry and Molecular Toxicology
  • Genotoxicity Testing
  • Mammalian Cell Assays

Background:

  • The L5178Y mouse lymphoma cell line is a key system for assessing mutagenicity.
  • The thymidine kinase (TK) locus assay (TK+/- to TK-/-) quantifies forward mutations.
  • TK-competent cells phosphorylate nucleoside analogs, enabling selection of TK-deficient mutants.

Purpose of the Study:

  • To evaluate the utility of the L5178Y/TK+/- assay in mutagenicity screening.
  • To assess the performance of the assay against existing in vivo carcinogenicity data.
  • To determine the assay's suitability as part of a broader mutagenicity/carcinogenicity testing battery.

Main Methods:

  • Utilized a near-diploid L5178Y mouse lymphoma cell line for TK locus mutation analysis.
  • Evaluated 48 chemical agents, assessing forward mutations at the heterozygous TK locus.
  • Compared assay results with in vivo carcinogenicity data for 44 of the tested agents.

Main Results:

  • The assay identified 39 out of 48 agents as positive mutagens, with 1 negative and 4 inconclusive results.
  • Correlation with carcinogenicity data revealed 2 definite false positives (sodium azide, methotrexate) and 1 definite false negative (1,1-dimethylhydrazine).
  • The assay demonstrated versatility across various chemical classes, excluding thymidine analogs.

Conclusions:

  • The L5178Y/TK+/- assay is a valuable tool for mutagenicity screening.
  • The assay shows promise for inclusion in a battery approach for carcinogenicity assessment.
  • Further investigation is needed to refine understanding of discrepancies with carcinogenicity data.

Related Concept Videos